Financial Data and Key Metrics Changes - Revenue for FY 2025 was $165.2 million, down 22% from the prior year [17] - Net loss after tax was €2.9 million, an improvement from a €10 million loss in the previous year [17] - Operating expenses were reduced by £6 million through property consolidation and resizing support teams [17][18] - No dividend was declared for the year ending March 31, 2025, reflecting a prudent approach due to uncertain economic conditions [13][17] Business Line Data and Key Metrics Changes - AWF delivered improved profitability year on year despite a challenging environment [21] - Madison launched a greenfield health channel and secured a place on two key panels within the health sector [22] - Jackson Stone and Wellington were significantly impacted by government spending reductions [23] - Absolute IT was hardest hit nationally but retained key capabilities [23] Market Data and Key Metrics Changes - Unemployment rates reached 5.1% in March, reflecting a 53% increase over two years [25] - The labor market showed signs of strain, with a notable increase in tender activity and preferred supplier contract awards [29] - The contractor book reduced as clients implemented cost control measures [21] Company Strategy and Development Direction - The company is focused on financial sustainability, recovery, and growth, with an emphasis on maintaining operational capacity without compromising service quality [15][18] - Strategic focus on sectors with long-term robustness, including infrastructure, health, and professional services [20] - The company aims to leverage AI and digitization to enhance operational efficiency while maintaining a human touch in recruitment processes [42][43] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the prolonged and challenging trading cycle but expressed optimism about future recovery [14][15] - The company is preparing for better economic conditions, with expectations for FY 2026 to be a year of rebuild and improved financial performance [25][44] - Management emphasized the importance of maintaining strong relationships with clients and focusing on high-value roles [30][32] Other Important Information - The company maintained a strong banking relationship with ASB, with facilities extending to April 2026 [18] - Continuous conversations with ASB are aimed at reducing net debt and improving gearing metrics [19] Q&A Session Summary Question: Concerns about capital and debt levels - A shareholder expressed concerns about the company's capital needs and suggested that more capital is necessary to navigate current challenges [67][68] - Management acknowledged the importance of retaining quality staff and emphasized that the company does not need to be capital intensive [82][84] Question: Impact of AI on service delivery - A shareholder inquired about how AI might fine-tune the company's processes and operations [92] - Management discussed the integration of AI into core operating platforms to enhance efficiency while maintaining a human touch in recruitment [43][96]

Financial Data and Key Metrics Changes - Revenue for FY 2025 was $165.2 million, down 22% from the prior year [17] - Net loss after tax was €2.9 million, an improvement from a €10 million loss in the previous year [17] - Operating expenses were reduced by £6 million through property consolidation and resizing support teams [18] - No dividend was declared for the year ending March 31, 2025, reflecting a prudent approach due to uncertain economic conditions [17][13] Business Line Data and Key Metrics Changes - AWF delivered improved profitability year on year despite a challenging environment, focusing on efficiency and quality business [22] - Madison strengthened its position in mid-senior recruitments and launched a new health channel, securing a place on key panels [22][23] - Jackson Stone and Wellington were significantly impacted by government spending reductions, affecting permanent and contract hires [24] - Absolute IT faced the hardest hit nationally but retained key capabilities [24] Market Data and Key Metrics Changes - Unemployment rates reached 5.1%, a 53% increase over two years, reflecting a seismic shift in the labor market [26] - The labor market participation rate decreased, indicating potential underreporting of unemployment figures [28] - ANZ's business outlook showed a dip in employment intentions, indicating nervousness in hiring across sectors [30] Company Strategy and Development Direction - The company is focusing on high-value roles and longer-term contingent workforce solutions to provide clients with necessary flexibility [32] - There is a strategic emphasis on sectors with greater long-term robustness, such as infrastructure and health [21] - The company aims to leverage its scale as New Zealand's largest recruitment business to capture more opportunities [33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the prolonged and challenging trading cycle but emphasized a positive leadership approach [15] - The focus remains on financial sustainability, recovery, and growth, with expectations for better performance in FY 2026 and stronger in FY 2027 [26][50] - Management is preparing for an eventual economic rebound, despite current market instability [30][47] Other Important Information - The company is actively working on extending banking facilities with ASB to support growth and reduce interest costs [19] - There is a commitment to maintaining a strong banking relationship and avoiding delinquent debt [19] Q&A Session Summary Question: Concerns about capital requirements and company debt - A shareholder expressed concerns about the company's capital needs and suggested that additional capital could help address current challenges [72][74] - Management acknowledged the importance of retaining quality staff and emphasized that the company does not need to be capital-intensive [86][90] Question: Impact of AI on recruitment processes - A shareholder inquired about how AI might fine-tune recruitment processes and improve operational efficiency [96] - Management discussed ongoing digitization efforts and the integration of AI to enhance recruitment capabilities while maintaining the human touch [45][46]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving agilon health, Inc. and its officers or directors [1] Company Developments - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director of the Board [3] - Following the leadership change, agilon suspended its full-year 2025 financial guidance due to ongoing market uncertainty and the need to optimize operating performance [3] - The stock price of agilon fell by $0.93 per share, a decrease of 51.51%, closing at $0.88 per share on August 5, 2025 [3] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - DJS Law Group is investigating Agilon Health, Inc. for potential violations of securities laws following significant leadership changes and a withdrawal of earnings guidance, which led to a sharp decline in the company's stock price [1][2]. Investigation Details - The investigation centers on whether Agilon made misleading statements or failed to disclose critical information to investors [2]. - On August 4, 2025, Agilon announced the resignation of President, CEO, and Board Director Steven Sell, which coincided with the release of its second quarter 2025 earnings results [2]. - Agilon also withdrew its previous full year 2025 earnings guidance, resulting in a more than 27% drop in shares during after-hours trading [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Agilon Health, Inc. for possible violations of federal securities laws following significant leadership changes and a withdrawal of earnings guidance, which led to a sharp decline in the company's stock price [2][3]. Group 1: Company Developments - On August 4, 2025, Agilon Health, Inc. announced the resignation of its President, CEO, and Board Director, Steven Sell, which surprised the market [3]. - The company also released its second-quarter 2025 financial results and withdrew its previously issued full-year 2025 earnings guidance, contributing to a more than 27% drop in share price during after-hours trading [3]. Group 2: Legal Investigation - The investigation by Bragar Eagel & Squire focuses on whether Agilon failed to disclose material information regarding the leadership transition and guidance withdrawal, potentially violating federal securities laws [2][3]. - Investors who suffered losses due to these developments are encouraged to contact the law firm to discuss their legal rights and options [4].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. regarding potential securities fraud or unlawful business practices [1] - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director, leading to a suspension of its full-year 2025 financial guidance [3] - Following the leadership change announcement, agilon's stock price dropped by $0.93, or 51.51%, closing at $0.88 per share on August 5, 2025 [3] Company Developments - The investigation by Pomerantz LLP focuses on whether agilon and its officers/directors engaged in misconduct [1] - The leadership change at agilon is part of a broader evaluation of actions to optimize operating performance amid market uncertainty [3] - The suspension of financial guidance indicates potential challenges in achieving previously set performance targets [3]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Agilon Health, Inc. regarding possible violations of federal securities laws following significant leadership changes and financial disclosures that negatively impacted the company's stock price [1][3]. Company Developments - On August 4, 2025, Agilon Health, Inc. announced the resignation of its President, CEO, and Board Director, Steven Sell, from all positions [3]. - The company released its second-quarter 2025 financial results and withdrew its previously issued full-year 2025 earnings guidance, which surprised the market [3]. - Following these announcements, Agilon's share price fell by more than 27% in after-hours trading [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether Agilon failed to disclose material information to investors regarding the timing, circumstances, or implications of its leadership transition and guidance withdrawal, potentially violating federal securities laws [3].

Group 1 - The core issue involves an investigation by Holzer & Holzer, LLC into agilon health, inc. regarding potential compliance with federal securities laws following the resignation of its CEO and President [1] - On August 4, 2025, agilon health announced the suspension of its previously issued full-year 2025 financial guidance and related assumptions, which led to a decline in the company's stock price [1] - The law firm Holzer & Holzer has a history of representing shareholders and investors in litigation, including shareholder class action and derivative litigation, and has recovered hundreds of millions of dollars for victims of corporate misconduct [3]

Core Viewpoint - Agilon Health reported weaker-than-expected earnings for Q2 2025, with significant declines in revenue and profitability metrics, leading to the withdrawal of its full-year financial guidance due to ongoing challenges and a leadership transition [1][10]. Financial Performance - GAAP revenue for Q2 2025 was $1.39 billion, missing the consensus estimate of $1.47 billion by approximately 5.2% and representing a 6.0% decline year-over-year from $1.48 billion in Q2 2024 [1][5]. - GAAP earnings per share (EPS) were $(0.25), a significant drop of 257.1% compared to $(0.07) in Q2 2024 [2]. - Gross profit turned negative at $(52) million, down from a positive $32 million in Q2 2024 [6]. - Adjusted EBITDA was $(83) million, worsening from a $(3) million loss in the same quarter last year [6]. Membership and Market Dynamics - Total platform membership decreased by 5% to 614,000, with a 3% decline in Medicare Advantage members and a 12% drop in ACO REACH members [5]. - The decline in membership was anticipated due to market and payer exits, but the extent of the contraction was notable [5]. Operational Challenges - The company faced retroactive adjustments that negatively impacted financial results, including a $66 million charge related to prior period expense developments [7]. - A $37 million reduction in risk adjustment revenue for 2024 was identified due to new data revealing overestimations in prior risk-based contracts [7]. - General and administrative expenses decreased by approximately 19% year-over-year to $56.3 million, while medical services expenses increased by 5.2% [9]. Leadership and Strategic Focus - A leadership change occurred with CEO Steven Sell stepping down, and Board Chairman Ronald A. Williams taking over as Executive Chair on an interim basis [10]. - The company is focusing on enhancing its data platform technology, which now covers 72% of membership, to improve risk management and operational visibility [11]. Future Outlook - The company has suspended its full-year financial guidance due to uncertainties surrounding performance visibility and leadership transition [15]. - Management anticipates potential tailwinds beginning in 2026, including changes to Medicare's reimbursement model and new clinical initiatives [16]. - Cash flow, profitability, and membership growth are expected to remain under pressure until strategic efforts take effect [16].

Core Insights - Agilon Health (AGL) reported $1.39 billion in revenue for the quarter ended June 2025, reflecting a year-over-year decline of 5.9% [1] - The earnings per share (EPS) for the same period was -$0.25, compared to -$0.07 a year ago, indicating a significant deterioration in profitability [1] - The reported revenue was a surprise of -4.98% compared to the Zacks Consensus Estimate of $1.47 billion, while the EPS surprise was -127.27% against the consensus estimate of -$0.11 [1] Financial Performance Metrics - The average number of Medicare Advantage members was 498,000, slightly above the average estimate of 493,100 based on two analysts [4] - Other operating revenues were reported at $2.94 million, which is lower than the estimated $3.16 million by five analysts, representing a year-over-year decline of 7.4% [4] - Medical services revenues were $1.39 billion, compared to the average estimate of $1.46 billion from five analysts, also reflecting a year-over-year decrease of 5.9% [4] Stock Performance - Agilon's shares have returned -30% over the past month, contrasting with the Zacks S&P 500 composite's +0.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]